EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 37 / Numéro 1 (Janvier 2021) Med Sci (Paris), 37 1 (2021) 53-58 Références
Open Access
Numéro
Med Sci (Paris)
Volume 37, Numéro 1, Janvier 2021
Page(s) 53 - 58
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020261
Publié en ligne 25 janvier 2021
  1. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Disco 2020; 19 : 277–89. [CrossRef] [Google Scholar]
  2. De Nobel E, Van’t Laar A. The size of the loading dose as an important determinant of the results of the oral glucose tolerance test. A study in subjects with slightly impaired glucose tolerance. Diabetes 1978 ; 27 : 42–48. [CrossRef] [PubMed] [Google Scholar]
  3. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964 ; 24 : 1076–1082. [CrossRef] [PubMed] [Google Scholar]
  4. Mcintyre N, Holdsworth C, Turner D. New interpretation of oral glucose tolerance. Lancet 1964 ; 284 : 20–21. [CrossRef] [Google Scholar]
  5. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019 ; 30 : 72–130. [CrossRef] [PubMed] [Google Scholar]
  6. Andersen A, Lund A, Knop FK, et al. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018 ; 14 : 390–403. [CrossRef] [PubMed] [Google Scholar]
  7. Gasbjerg LS, Bergmann NC, Stensen S, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides 2020; 125 : 170183. [CrossRef] [PubMed] [Google Scholar]
  8. Stemmer K, Müller TD, DiMarchi RD, et al. CNS-targeting pharmacological interventions for the metabolic syndrome. J Clin Invest 2019 ; 129 : 4058–4071. [CrossRef] [PubMed] [Google Scholar]
  9. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020 ; 41 : 255–323. [CrossRef] [Google Scholar]
  10. Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet 2019 ; 58 : 781–791. [CrossRef] [PubMed] [Google Scholar]
  11. Alani AWG, Robinson JR. Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative. Pharm Res 2008 ; 25 : 48–54. [CrossRef] [PubMed] [Google Scholar]
  12. Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial. JAMA 2017 ; 318 : 1460–1470. [CrossRef] [PubMed] [Google Scholar]
  13. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019 ; 381 : 841–851. [CrossRef] [Google Scholar]
  14. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019 ; 394 : 39–50. [CrossRef] [PubMed] [Google Scholar]
  15. O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018 ; 392 : 637–649. [CrossRef] [PubMed] [Google Scholar]
  16. Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2020; 8 : 392–406. [CrossRef] [PubMed] [Google Scholar]
  17. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA 2019 ; 321 : 1466–1480. [CrossRef] [PubMed] [Google Scholar]
  18. Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019 ; 7 : 528–539. [CrossRef] [PubMed] [Google Scholar]
  19. Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 2019 ; 42 : 2272–2281. [CrossRef] [PubMed] [Google Scholar]
  20. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 trial. Diabetes Care 2019 ; 42 : 2262–2271. [CrossRef] [PubMed] [Google Scholar]
  21. Hunt B, Hansen BB, Ericsson Å, et al. Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States. Adv Ther 2019 ; 36 : 3483–3493. [CrossRef] [PubMed] [Google Scholar]
  22. Thorens B. Incrétines, sécrétion d’insuline et diabète. Med Sci (Paris) 2003 ; 19 : 860–863. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.